



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Information under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/598,449	
			Filing Date	August 30, 2006	
			First Named Inventor	Hamed Aissaoui	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	A0345.0027

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.†	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.†	Foreign Patent Document Country Code* Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T‡
	BA	WO-97/20789 (w/ corresponding European Application Publication EP 0 916 637 A1)	06-12-1997	Japan Science & Tech Corp et al.		
	BB	WO-99/09024-A1	02-25-1999	SmithKline Beecham PLC		
	BC	WO-00/47576-A1	08-17-2000	Smithkline Beecham PLC		
	BD	WO-00/47580-A2	08-17-2000	Smithkline Beecham PLC		
	BE	WO-01/85693-A1 (w/ corresponding European Application Publication EP 1 288 202)	11-15-2001	Banyu Pharmaceutical Co., Ltd.		
	BF	WO-01/96302-A1	12-20-2001	Smithkline Beecham PLC		
	BG	WO-02/44172-A1	06-06-2002	Smithkline Beecham PLC		
	BH	WO-02/090355-A1	11-14-2002	Smithkline Beecham Plc et al.		
	BI	WO-03/002559-A2	01-09-2003	Smithkline Beecham Plc et al.		
	BJ	WO-03/002561-A1	01-09-2003	Smithkline Beecham Plc et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw lines through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). ‡See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T‡
	CA	Sakurai, T. et al.; "Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate Feeding Behavior"; Cell, Vol. 92, pages 573-585, February 20, 1998.			
	CB	Chemelli, R. et al.; "Narcolepsy in orexin Knockout Mice: Molecular Genetics of Sleep Regulation"; Cell, Vol. 98, pages 437-451, August 20, 1999.			
	CC	Kobershtein, R. et al.; "Tetrahydroisoquinolines as Orexin Receptor Antagonists: Strategies for Lead Optimization by Solution-Phase Chemistry"; Chimia 57 (2003), pages 270-275.			
	CD	Gould, P.; "Salt selection for basic drugs"; International Journal of Pharmaceutics"; 33 (1986), pages 201-217.			
	CE	Remington: The Science and Practice of Pharmacy, 20th Edition, 2001, Marck Publishing Company, Easton, Pennsylvania.			
Examiner Signature	/Zinna Davis/ (08/14/2009)			Date Considered	



PTO/SB/08A/B (09-06)
 Approved for use through 03/31/2007. OMB 0851-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/598,449	
			Filing Date	August 30, 2006	
			First Named Inventor	Hamed Aissaoui	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	A0345.0027

	CF	Uematsu, N. et al.; "Asymmetric Transfer Hydrogenation of Imines"; <i>J. Am. Chem. Soc.</i> 1996 , 118, pages 4916-4917.	
--	----	---	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Zinna Davis/ (08/14/2009)	Date Considered	
--------------------	----------------------------	-----------------	--

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZD/

POCSNY 23862-01